This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Heidelberg University Researchers Present Data On MiRview Mets Assay At Neuroweek Conference

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the results of a two-phased, post-marketing validation study using the Company’s miRview™ mets assay have been presented at the “Neuroweek” conference in Mannheim, Germany by lead investigator, Dr. Wolf C. Mueller from the Department of Neuropathology at Heidelberg University in Germany, “Neuroweek” is a joint meeting of German medical societies focused on neurology-related disease management and research. It consists of the Annual Congress of the German Society of Neurology, the Annual Conference of the German Society of Neuropathology and Neuroanatomy, as well as the Annual Meetings of the German Societies of Neurosurgeons, Neuropediatricians and Neuroradiologists.

The study consisted of a proof-of-concept phase and a validation phase. In the proof-of-concept phase, brain and spine metastases from known primary tumors were analyzed with the miRview™ mets assay. In the validation phase of the study, a cohort of brain and spine metastatic samples of true Cancer of Unknown Primary (CUP) patients were studied, and concordance between results generated by miRview™ mets and the clinical and pathological evaluation was examined.

Results from the validation phase demonstrated that primary origin prediction from miRview™ mets was in agreement with the clinical or pathological evaluation in 80% of the cases.

“Knowing the origin of a metastasis affects treatment decisions, and CUP patients may undergo a wide range of costly and time-consuming tests to identify the primary site of origin, often to no avail. Consequently, we are extremely pleased with the positive results of this study, which demonstrate the ability of miRview™ mets to assist physicians in accurately identifying the origin of metastases in true CUP patients,” noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. “This is the second post-marketing validation study we have completed with a leading cancer center focusing on miRview™ mets and its ability to accurately identify the origin of metastases in CUP, and we are gratified to see the consistently strong performance of our microRNA-based assay. Literature has shown microRNAs to be highly tissue specific, and we believe that our sensitive, proprietary microRNA technology is enabling us to harness their power to develop diagnostic tools with high accuracy for the benefit of patients worldwide.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ROSG $1.44 1.41%
AAPL $117.81 -0.19%
FB $105.45 0.04%
GOOG $750.26 0.28%
TSLA $231.61 0.86%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs